Bacteriophages Therapy Market - 2024-2031
The Bacteriophages Therapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Bacteriophages Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product
Both primary and secondary data sources have been used in the global Bacteriophages Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
A Bacteriophages Therapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product
- Phage Cocktails*
- Phage Sprays
- Phage Tablets & Capsules
- Others
- Oral*
- Topical
- Parenteral
- Staphylococci*
- Streptococci
- Escherichia coli
- Other Bacterial Pathogens
- Urinary Tract Infections*
- Infected Burn Wounds
- Chronic Otitis
- Chronic Venous Leg Ulcers
- Chronic Rhinosinusitis
- Hospitals & Clinics*
- Specialty Centers
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Bacteriophages Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Product
3.2. Snippet by Route of Administration
3.3. Snippet by Targeted Bacteria
3.4. Snippet by Disease Indication
3.5. Snippet by End User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the incidence of infectious diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High cost of development and production
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Phage Cocktails*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Phage Sprays
7.4. Phage Tablets & Capsules
7.5. Others
8. BY ROUTE OF ADMINISTRATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Parenteral
9. BY TARGETED BACTERIA
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
9.1.2. Market Attractiveness Index, By Targeted Bacteria
9.2. Staphylococci*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Streptococci
9.4. Escherichia coli
9.5. Other Bacterial Pathogens
10. BY DISEASE INDICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
10.1.2. Market Attractiveness Index, By Disease Indication
10.2. Urinary Tract Infections*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Infected Burn Wounds
10.4. Chronic Otitis
10.5. Chronic Venous Leg Ulcers
10.6. Chronic Rhinosinusitis
11. BY END-USER
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals & Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Centers
11.4. Others
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.9.1. Germany
12.3.9.2. UK
12.3.9.3. France
12.3.9.4. Italy
12.3.9.5. Spain
12.3.9.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.9.1. Brazil
12.4.9.2. Argentina
12.4.9.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. COMPANY PROFILES
14.1. Eliava Biopreparation LLC*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. BiomX Ltd., Phi Therapeutics
14.3. TechnoPhage
14.4. Intralytix, Inc.
14.5. Locus Biosciences, Inc.
14.6. TechnoPhage SA
14.7. Eligo Bioscience
14.8. Armata Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Product
3.2. Snippet by Route of Administration
3.3. Snippet by Targeted Bacteria
3.4. Snippet by Disease Indication
3.5. Snippet by End User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the incidence of infectious diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High cost of development and production
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY PRODUCT
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Phage Cocktails*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Phage Sprays
7.4. Phage Tablets & Capsules
7.5. Others
8. BY ROUTE OF ADMINISTRATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Parenteral
9. BY TARGETED BACTERIA
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
9.1.2. Market Attractiveness Index, By Targeted Bacteria
9.2. Staphylococci*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Streptococci
9.4. Escherichia coli
9.5. Other Bacterial Pathogens
10. BY DISEASE INDICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
10.1.2. Market Attractiveness Index, By Disease Indication
10.2. Urinary Tract Infections*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Infected Burn Wounds
10.4. Chronic Otitis
10.5. Chronic Venous Leg Ulcers
10.6. Chronic Rhinosinusitis
11. BY END-USER
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals & Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Centers
11.4. Others
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.9.1. Germany
12.3.9.2. UK
12.3.9.3. France
12.3.9.4. Italy
12.3.9.5. Spain
12.3.9.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.9.1. Brazil
12.4.9.2. Argentina
12.4.9.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Targeted Bacteria
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. COMPANY PROFILES
14.1. Eliava Biopreparation LLC*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. BiomX Ltd., Phi Therapeutics
14.3. TechnoPhage
14.4. Intralytix, Inc.
14.5. Locus Biosciences, Inc.
14.6. TechnoPhage SA
14.7. Eligo Bioscience
14.8. Armata Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
